The U.S. Food and Drug Administration has issued a warning to ImmunityBio, alleging that a direct-to-consumer TV ad and podcast promoting Anktiva were false or misleading and misbranded the drug under federal law. The agency also highlighted that the promotional content implied unapproved methods of administration and did not adequately disclose risks associated with the drug. The FDA has requested immediate action to address these violations.